Logo image of MDCX

MEDICUS PHARMA LTD (MDCX) Stock Fundamental Analysis

NASDAQ:MDCX - Nasdaq - CA58471K2020 - Common Stock - Currency: USD

4.33  +0.06 (+1.41%)

Fundamental Rating

1

Taking everything into account, MDCX scores 1 out of 10 in our fundamental rating. MDCX was compared to 563 industry peers in the Biotechnology industry. The financial health of MDCX is average, but there are quite some concerns on its profitability. MDCX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year MDCX has reported negative net income.
MDCX had a negative operating cash flow in the past year.
MDCX had negative earnings in each of the past 5 years.
In the past 5 years MDCX always reported negative operating cash flow.
MDCX Yearly Net Income VS EBIT VS OCF VS FCFMDCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

MDCX has a worse Return On Assets (-205.02%) than 90.76% of its industry peers.
MDCX has a Return On Equity of -335.87%. This is in the lower half of the industry: MDCX underperforms 75.31% of its industry peers.
Industry RankSector Rank
ROA -205.02%
ROE -335.87%
ROIC N/A
ROA(3y)-358.98%
ROA(5y)-4285.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MDCX Yearly ROA, ROE, ROICMDCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MDCX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDCX Yearly Profit, Operating, Gross MarginsMDCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

4

2. Health

2.1 Basic Checks

The number of shares outstanding for MDCX has been increased compared to 1 year ago.
The number of shares outstanding for MDCX has been increased compared to 5 years ago.
MDCX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MDCX Yearly Shares OutstandingMDCX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MDCX Yearly Total Debt VS Total AssetsMDCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

MDCX has an Altman-Z score of 3.03. This indicates that MDCX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.03, MDCX is in the better half of the industry, outperforming 76.91% of the companies in the same industry.
MDCX has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.07, MDCX is doing worse than 63.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 3.03
ROIC/WACCN/A
WACCN/A
MDCX Yearly LT Debt VS Equity VS FCFMDCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

2.3 Liquidity

MDCX has a Current Ratio of 2.73. This indicates that MDCX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.73, MDCX is doing worse than 68.21% of the companies in the same industry.
A Quick Ratio of 2.73 indicates that MDCX has no problem at all paying its short term obligations.
MDCX's Quick ratio of 2.73 is on the low side compared to the rest of the industry. MDCX is outperformed by 66.61% of its industry peers.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.73
MDCX Yearly Current Assets VS Current LiabilitesMDCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

1

3. Growth

3.1 Past

MDCX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.18%, which is quite impressive.
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MDCX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.78% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60.34%
EPS Next 2Y28.09%
EPS Next 3Y17.78%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDCX Yearly EPS VS EstimatesMDCX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

0

4. Valuation

4.1 Price/Earnings Ratio

MDCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDCX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDCX Price Earnings VS Forward Price EarningsMDCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDCX Per share dataMDCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as MDCX's earnings are expected to grow with 17.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.09%
EPS Next 3Y17.78%

0

5. Dividend

5.1 Amount

No dividends for MDCX!.
Industry RankSector Rank
Dividend Yield N/A

MEDICUS PHARMA LTD

NASDAQ:MDCX (5/8/2025, 1:12:37 PM)

4.33

+0.06 (+1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/amc
Earnings (Next)05-29 2025-05-29
Inst Owners13.86%
Inst Owner ChangeN/A
Ins Owners18.6%
Ins Owner Change0%
Market Cap58.07M
Analysts82.22
Price Target12.24 (182.68%)
Short Float %0.6%
Short Ratio0.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-161.54%
Min EPS beat(2)-204.81%
Max EPS beat(2)-118.27%
EPS beat(4)1
Avg EPS beat(4)-79.52%
Min EPS beat(4)-204.81%
Max EPS beat(4)19.39%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 16.63
P/tB 16.63
EV/EBITDA N/A
EPS(TTM)-2.01
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-0.77
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS0
BVpS0.26
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -205.02%
ROE -335.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-358.98%
ROA(5y)-4285.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.73
Altman-Z 3.03
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.27%
EPS Next Y60.34%
EPS Next 2Y28.09%
EPS Next 3Y17.78%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-618.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-467.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-467.77%
OCF growth 3YN/A
OCF growth 5YN/A